Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-05-05 (thepharma.media)
Biogen quarterly profit exceeded forecasts due to success in the segment of orphan diseases - Media
At the same time, the company activated efforts to promote existing drugs and has recently acquired new assets.
Read more
2025-04-14 (centerforbiosimilars.com)
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Read more
2025-04-03 (femtechinsider.com)
What's New in Femtech This Week? (April 3, 2025) | Femtech Insider
Every Thursday we send out a curated newsletter on all things femtech and women's health innovation. This is an excerpt from the latest edition. If you'd like to subscribe, you can do so at the bottom of this page. Highlights Women's healthtech company Fizimed raises €4M for international expansion. PE Firm Astorg combined multiple reproductive health medtech businesses; launches Nexpring Health.
Read more
2024-07-30 (reuters.com)
Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest
The benefit of Eisai and Biogen's Alzheimer's drug Leqembi in patients with early-stage Alzheimer's appears to increase with continued use with no new safety issues, according to three-year data presented at an Alzheimer's meeting on Tuesday.
Read more
2024-07-26 (prnewswire.com)
A New Era of Healthcare in Kazakhstan: Astana Genetic Center Laboratory to Offer State-of-the-Art Genetic Testing
/PRNewswire/ -- BGI Genomics announced on July 18, in partnership with Technopark Biogen, the opening of the Astana Genetic Center (AGC) - a state-of-the-art...
Read more
2024-07-23 (eurekalert.org)
Transforming healthcare in Kazakhstan: Launch of the Astana Genetic Center, an advanced genetic testing laboratory
On July 18, BGI Genomics announced the opening of the Astana Gene Center (AGC), a world-class genetic laboratory in Astana, Kazakhstan, with the aim of promoting the development of preventive medicine in Kazakhstan.
Read more
2024-05-20 (reuters.com)
US FDA approves two biosimilars for blockbuster eye drug Eylea
The U.S. Food and Drug Administration (FDA) on Monday approved two close copies of Regeneron Pharmaceuticals' Eylea, its first-ever clearance to biosimilar versions of the blockbuster eye treatment.
Read more
2024-04-03 (maidenhead-advertiser.co.uk)
Global biotechnology firm opens new UK and Ireland headquarters in Maidenhead
Biogen UK, the UK arm of Biogen, helps research and develop treatments for conditions including Alzheimer’s and Multiple Sclerosis (MS).
Read more
2024-03-22 (reuters.com)
EU regulator delays decision on Eisai-Biogen Alzheimer's drug |
The European Union's medicines regulator has delayed its decision on Eisai and partner Biogen's Alzheimer's disease drug that was expected this week, the Japanese company said on Friday.
Read more
2023-08-05 (reuters.com)
FDA approves oral pill for postpartum depression for first time
In 2021, an estimated 21 million adults in the United States had at least one episode of major depressive disorder. PPD affects around one in seven new mothers.
Read more
2023-07-07 (finanznachrichten.de)
Opening Bell: Biogen, Apple, Alibaba, First Solar
Resurgent interest rate concerns caused losses on Wall Street yesterday. The Dow Jones ended trading 1.1 percent weaker. The Nasdaq lost 0.8 percent. The individual topics are what matters today
Read more
2018-06-07 (fiercebiotech.com)
Servier opens Kendall Square site, plans Chinese office to access external innovation
Servier has opened a site in Kendall Square and staffed it with people from | Servier has opened a site in Kendall Square and staffed it with people from Biogen and the University of Massachusetts to find R&D and licensing opportunities.
Read more